Noema Pharma Announces Leadership Change in R&D
Noema Pharma, a promising clinical-stage biotech firm focused on innovative treatments for central nervous system (CNS) conditions, has appointed Volker Knappertz, M.D., as its Executive Vice President of Research & Development. This pivotal role marks an important step for the company as it seeks to advance its therapeutic pipeline.
Volker Knappertz: An Experienced Addition
With over 25 years of experience in drug development, Dr. Knappertz brings a wealth of knowledge to Noema Pharma. Known for his strong leadership skills, he has played a significant role in numerous new drug applications and approvals throughout his career.
Previous Accomplishments
Before joining Noema, Dr. Knappertz served as Executive Vice President at Aurinia Pharmaceuticals. He oversaw the R&D portfolio targeting autoimmune diseases and was pivotal in leading teams to success. His role at GW Pharmaceuticals—a company known for its ground-breaking Epidiolex—was vital in shifting its focus from botanical products to fully integrated biopharmaceuticals.
Expertise in CNS Development
Dr. Knappertz's expertise in CNS development will be crucial for Noema Pharma as it embarks on an impactful year. With multiple Phase 2 studies underway, his role will encompass overseeing various clinical trials ranging from treatments for seizures in Tuberous Sclerosis Complex to pain relief in Trigeminal Neuralgia.
The Vision for Noema Pharma
Noema is recognized for its commitment to patients and innovation in treating CNS disorders. The first-in-disease therapies in the company’s late-stage pipeline underscore its dedication to addressing previously unmet medical needs. Dr. Knappertz shares this vision and looks forward to advancing these critical therapeutics.
Fostering Collaboration
Collaboration will be at the heart of Dr. Knappertz's strategy as he integrates into Noema's existing team. He aims to leverage the collective experience of the team to not only meet clinical milestones but to surpass them, ensuring that promising therapies reach the patients who need them most.
About Noema Pharma's Mission
Noema Pharma is fully committed to pioneering transformative therapeutics in neuroscience. With several programs currently engaged in Phase 2 clinical trials, the potential to make significant advancements in the treatment landscape for CNS disorders is within reach. These trials particularly target conditions like seizures due to Tuberous Sclerosis Complex and other neurological challenges.
Investment and Growth
Noema was founded by Sofinnova Partners and continues to gain support from esteemed investment firms. With current investors such as EQT Life Sciences and others actively backing Noema, the company is poised for growth. The ongoing commitment from stakeholders highlights a strong confidence in Noema's approach and future.
Frequently Asked Questions
1. What is Noema Pharma's primary focus?
Noema Pharma focuses on developing innovative treatments for central nervous system disorders with high unmet medical needs.
2. Who is Volker Knappertz, M.D.?
Dr. Volker Knappertz is the newly appointed Executive Vice President of Research & Development at Noema Pharma, with extensive experience in drug development.
3. What significant trials is Noema Pharma currently conducting?
Noema Pharma is conducting Phase 2 clinical trials for conditions like Tuberous Sclerosis Complex seizures and Trigeminal Neuralgia pain relief.
4. How does Noema Pharma ensure patient-centric solutions?
Noema Pharma prioritizes patient needs by developing first-in-disease therapeutics and engaging in rigorous clinical trials.
5. What investment firms support Noema Pharma?
Noema Pharma is supported by investors including EQT Life Sciences, Forbion, and others who share a vision of advancing CNS therapeutics.
